SCHEMBL3979263

SCHEMBL3979263

CC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2OC[C@@H]4C)CC1(C)N

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 2/20 0.71
KDM4E B2RXH2 7/20 0.70
ALDH1A1 P00352 6/20 0.70
HPGD P15428 4/20 0.70
HSD17B10 Q99714 2/20 0.70
ALB P02768 1/20 0.70
HRH3 Q9Y5N1 1/20 0.70
POLB P06746 2/20 0.69
TUBB4A P04350 1/20 0.69
TUBB P07437 1/20 0.69
TUBA3C P0DPH7 1/20 0.69
TUBA1B P68363 1/20 0.69
TUBA4A P68366 1/20 0.69
TUBB4B P68371 1/20 0.69
TUBB3 Q13509 1/20 0.69
TUBB2A Q13885 1/20 0.69
TUBB8 Q3ZCM7 1/20 0.69
TUBA3E Q6PEY2 1/20 0.69
TUBA1A Q71U36 1/20 0.69
SLC47A1 Q96FL8 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13576366 0.90 AADAT (0.75) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL3982593 0.90 AADAT (0.67) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL3979177 0.90 AADAT (0.67) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL3977395 0.90 AADAT (0.67) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL3983628 0.90 AADAT (0.67) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL3983522 0.89 AADAT (0.66) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL15090885 0.89 AADAT (0.56) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6009397 0.88 AADAT (0.69) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL15082009 0.87 AADAT (0.63) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL3980361 0.87 AADAT (0.70) AADATKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1882689-B1 TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2013-07-10 EP claimed
US-20090253726-A1 TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-10-08 US claimed
EP-1882689-A1 TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2008-01-30 EP claimed
US-20060264428-A1 Tri-, tetra-substituted-3-aminopyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-23 US claimed
EP-1882689-B1 TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2013-07-10 EP disclosed
US-8476429-B2 Tri-, tetra-substituted-3-aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-02 US disclosed
US-20120232288-A1 TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2012-09-13 US disclosed
US-8211910-B2 Tri-, tetra-substituted-3-aminopyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2012-07-03 US disclosed
EP-2463274-A1 Tri-or tetra-substituted-3-aminopyrrolidine deritatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-13 EP disclosed
US-20090253726-A1 TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-10-08 US disclosed
US-7563805-B2 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-07-21 US disclosed
EP-1882689-A1 TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2008-01-30 EP disclosed
US-20060264428-A1 Tri-, tetra-substituted-3-aminopyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264428-A1 Tri-, tetra-substituted-3-aminopyrrolidine derivative QTRT1, RRS1, LAS1L AADAT 1866/4885KDM4E 2926/4885ALDH1A1 3966/4885
US-20090253726-A1 TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE AAAS, NPEPPS, TEAD4 AADAT 186/4885KDM4E 3137/4885ALDH1A1 3018/4885
US-20120232288-A1 TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE TLR5, TEAD4, NAALAD2 AADAT 440/4885KDM4E 2911/4885ALDH1A1 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.